Craft
  • Home
  •  / Verastem Oncology
Verastem Oncology

Verastem Oncology

Phase II Trials Products

4

FY, 2020

Revenue

$2.1 M

FY, 2021

Market Capitalization

$204 M

2022-09-20

Verastem Oncology Summary

Company summary

Overview
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Its pipeline is focused on small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth inhibition. Verastem Oncology develops VS-6766, an orally available small molecule RAF/MEK inhibitor that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK; and defactinib, a targeted inhibitor of FAK that is a non-receptor tyrosine kinase encoded by the protein tyrosine kinase-2 (PTK-2) gene that is involved in cellular adhesion and, in cancer, metastatic capability.
Type
Public
Founded
2010
HQ
Needham, MA, US | view all locations
Website
https://www.verastem.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Brian Stuglik

    Brian Stuglik, Chief Executive Officer

  • Rob Gagnon

    Rob Gagnon, Chief Business and Financial Officer

    • Jonathan Pachter

      Jonathan Pachter, Chief Scientific Officer

    • Hagop Youssoufian

      Hagop Youssoufian, Head of Medical Strategy

    Operating MetricsView all

    Phase II Trials Products

    4

    FY, 2020

    Phase I/II Trials Products

    6

    FY, 2020

    LocationsView all

    2 locations detected

    • Needham, MA HQ

      United States

      117 Kendrick St

    • Walsrode, NDS

      Germany

      Lange Str. 70

    Verastem Oncology Financials

    Summary financials

    Net income (Q2, 2022)
    ($22.0M)
    Cash (Q2, 2022)
    $64.0M
    EBIT (Q2, 2022)
    ($21.4M)
    Enterprise value
    $170.6M

    Footer menu